Risk factors
Arcus Biosciences (RCUS) risk factors
Item 1A of every Arcus Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors56 risks5 new3 dropped16 reworded
Arcus Biosciences updated its risk profile around combination therapies, trade relations with China, and cash runway extensions.
Filed Feb 25, 2026 - FY2024 10-K risk factors54 risks
Arcus Biosciences faces high clinical and commercialization risks as a clinical-stage biopharmaceutical company with no approved products or revenue. The company relies heavily on its strategic collaboration with Gilead and key executives like CEO Terry Rosen. Substantial capital needs and complex global supply chains add ongoing operational uncertainty.
Filed Feb 25, 2025